ICSI study: Dual trigger vs HCG trigger
Official title Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
ClinicalTrials.gov ID: NCT07861399
What this study is testing
What is Dual trigger (human chorionic gonadotropin plus GnRH-agonist)?
An investigational combination trigger being studied for final oocyte maturation in ICSI cycles. It is designed to stimulate final oocyte maturation by using a GnRH agonist together with hCG to trigger ovulation.
Also referred to as Triptorelin acetate and human chorionic gonadotropin.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if using a dual trigger changes lab results and pregnancy outcomes compared to the standard hCG trigger.
- Who it's for
- Women who are normal responders and are having IVF or ICSI treatment.
- What's involved
- Participants will receive either a dual trigger or the usual hCG trigger during their egg‑retrieval cycle and will have standard monitoring and follow‑up visits.
- Time commitment
- The study follows participants through one IVF/ICSI cycle, with visits for the trigger, egg retrieval, and routine post‑procedure check‑ups.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 40, women only
You may be able to join if
- Women aged 20-40 years.
- Body mass index (BMI) between 18 and 30 kg/m².
- Undergoing ICSI treatment using a GnRH antagonist protocol.
- Normal ovarian reserve and expected normal ovarian response.
- AMH between 1.2 - 3.5 ng/ml
You likely can't join if
- Poor ovarian response (Bologna/POSEIDON criteria)
- High ovarian response with a risk of ovarian hyperstimulation syndrome (OHSS) AMH \> 3.5 ng/ml or AFC \> 15 follicle.
- Polycystic ovary syndrome (PCOS).
- Serum E2 level \> 3500 pg/ml at day of triggering.
- Endocrine disorders including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, or Cushing syndrome.
- Congenital uterine abnormalities.
See the full eligibility criteria
- Women aged 20-40 years.
- Body mass index (BMI) between 18 and 30 kg/m².
- Undergoing ICSI treatment using a GnRH antagonist protocol.
- Normal ovarian reserve and expected normal ovarian response.
- AMH between 1.2 - 3.5 ng/ml
- AFC 7-15 follicle.
- First or second ICSI cycle.
- Poor ovarian response (Bologna/POSEIDON criteria)
- High ovarian response with a risk of ovarian hyperstimulation syndrome (OHSS) AMH \> 3.5 ng/ml or AFC \> 15 follicle.
- Polycystic ovary syndrome (PCOS).
- Serum E2 level \> 3500 pg/ml at day of triggering.
- Endocrine disorders including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, or Cushing syndrome.
- Congenital uterine abnormalities.
- Severe systemic diseases affecting fertility outcomes.
The study team makes the final eligibility decision.
Where it is enrolling
- Cairo, Cairo Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Cairo, Cairo Governorate, Egypt. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.